Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18751006 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | October 2024 | Abandon | 4 | 1 | 0 | No | No |
| 18654709 | METHOD OF TREATING MIDDLE EAST RESPIRATORY SYNDROME (MERS) | May 2024 | December 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18688333 | NOVEL SALT OF 2-AMINO-2-(2-(1-DECYL-1H-1,2,3-TRIAZOL-4-YL)ETHYL)PROPANE-1,3-DIOL, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | February 2024 | May 2025 | Allow | 14 | 2 | 0 | No | No |
| 18519337 | METHOD OF PREPARING IONIC FLUIDS | November 2023 | June 2025 | Allow | 19 | 3 | 0 | No | Yes |
| 18378862 | 6-(6-BROMO-2-OXO-2H-CHROMEN-3-YL)-4-(3-BROMOPHENYL)-2- ALKOXYNICOTINONITRILE AS ANTIMICROBIAL COMPOUNDS | October 2023 | October 2024 | Allow | 13 | 3 | 0 | No | No |
| 18244446 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | September 2023 | January 2025 | Allow | 17 | 2 | 2 | Yes | No |
| 17972395 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | October 2022 | March 2025 | Allow | 29 | 3 | 1 | Yes | No |
| 17900405 | OPTIMIZED INGREDIENT MATRICES FOR ENHANCED HYDRATION AND MUSCLE RECOVERY PRE-, INTRA-, AND POST-EXERCISE | August 2022 | January 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17850593 | TREATMENT OF DISEASES INVOLVING MUCIN | June 2022 | March 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17848015 | PRODRUGS OF ACYL CARNITINES | June 2022 | April 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17847061 | TREATMENT FOR DISEASES CAUSED BY RNA VIRUSES | June 2022 | October 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17664759 | METHODS FOR SELECTING PHOSPHATASE SELECTIVE AND NON-SELECTIVE PHOSPHATASE INHIBITORS | May 2022 | March 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17747342 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | May 2022 | February 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17743035 | CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE | May 2022 | December 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17695796 | DP ANTAGONIST | March 2022 | January 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17592740 | TRANSDERMAL DELIVERY OF DICLOFENAC, CARBAMAZEPINE AND BENZYDAMINE | February 2022 | February 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17544616 | BENZENE DERIVATIVE | December 2021 | November 2024 | Allow | 35 | 1 | 0 | No | No |
| 17533674 | COMBINATION THERAPY FOR TREATING CANCER | November 2021 | January 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17521453 | METHODS AND MATERIALS FOR TREATING CALCIFIC AORTIC VALVE STENOSIS | November 2021 | May 2025 | Abandon | 42 | 3 | 0 | No | No |
| 17520952 | CANNABINOID RECEPTOR MODULATORS | November 2021 | January 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17488195 | Compositions for Improving Low Testosterone Levels | September 2021 | February 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17442351 | DEPSIDE TRIMERIC COMPOUNDS FOR SKELETAL MUSCLE MODULATION | September 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17468439 | CLINICAL ASSESSMENT OF CEREBRAL VASOSPASM RISK FOLLOWING ANEURYSMAL SUBARACHNOID HEMORRHAGE | September 2021 | August 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17374679 | PHARMACEUTICAL COMPOSITION AND METHOD FOR REGENERATING MYOFIBERS IN THE TREATMENT OF MUSCLE INJURIES | July 2021 | April 2025 | Allow | 46 | 1 | 1 | No | No |
| 17366839 | NASAL FORMULATIONS OF METOCLOPRAMIDE | July 2021 | November 2024 | Allow | 40 | 1 | 1 | No | No |
| 17366818 | NASAL FORMULATIONS OF METOCLOPRAMIDE | July 2021 | November 2024 | Allow | 40 | 1 | 1 | No | No |
| 17364695 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | June 2021 | March 2025 | Abandon | 45 | 2 | 0 | Yes | Yes |
| 17364585 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | June 2021 | January 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17364551 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | June 2021 | March 2024 | Allow | 33 | 1 | 0 | No | No |
| 17320543 | BIOACTIVE FORMULATION AND METHOD FOR PREPARATION THEREOF | May 2021 | February 2025 | Abandon | 45 | 3 | 0 | No | No |
| 17180136 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A RENAL DISEASE | February 2021 | April 2025 | Abandon | 49 | 3 | 0 | Yes | No |
| 17174764 | FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | February 2021 | June 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 16955806 | COMPOSITION FOR TREATING A PATIENT WITH A RESPIRATORY DISEASE CAUSED BY CHRONIC INFLAMMATION, PRODUCTION METHOD, AND USE OF SAID COMPOSITION | June 2020 | November 2024 | Abandon | 53 | 3 | 1 | No | No |
| 16649222 | METHODS AND PRODUCTS FOR IMPROVING SPERM QUALITY | March 2020 | March 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16624381 | COMBINATION COMPRISING DECANOIC ACID FOR THE TREATMENT OF EPILEPSY | December 2019 | January 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16713578 | OPTHALMIC COMPOSITIONS FOR INHIBITING CLOUDING OF THE OCULAR LENS | December 2019 | February 2025 | Abandon | 60 | 4 | 0 | Yes | No |
| 16563131 | CAPSAZEPINE ANALOGS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | September 2019 | March 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 15702319 | Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof | September 2017 | February 2020 | Allow | 29 | 2 | 1 | No | No |
| 15481596 | ANTIFUNGAL AGENTS AND USES THEREOF | April 2017 | February 2019 | Allow | 23 | 2 | 1 | Yes | No |
| 15470736 | THERAPEUTIC INHIBITORY COMPOUNDS | March 2017 | November 2018 | Allow | 20 | 1 | 1 | No | No |
| 15414838 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | January 2017 | September 2018 | Allow | 20 | 1 | 1 | Yes | No |
| 15088588 | Zinc or Copper (II) Salt and Use Thereof as a Biocide | April 2016 | July 2019 | Allow | 40 | 4 | 1 | No | No |
| 14824319 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | August 2015 | May 2017 | Allow | 21 | 1 | 1 | No | No |
| 14708424 | QUINOLINONE DERIVATIVES | May 2015 | August 2017 | Allow | 27 | 2 | 1 | No | No |
| 14429977 | CMPF AS A BIOMARKER FOR DIABETES AND ASSOCIATED METHODS | March 2015 | March 2017 | Allow | 24 | 1 | 1 | No | No |
| 14404330 | INHIBITORS OF THE NOTCH SIGNALING PATHWAY AND SECRETION FOR USE IN MEDICINE | November 2014 | August 2017 | Allow | 33 | 2 | 1 | Yes | No |
| 14378082 | METHODS, PHARMACEUTICAL COMPOSITIONS, THERAPEUTIC SYSTEMS, AND COMPOUNDS FOR TREATING B CELL MALIGNANCIES | August 2014 | May 2016 | Allow | 21 | 1 | 1 | No | No |
| 14232200 | USE AND AGROCHEMICAL COMPOSITION OF CARBOXYLIC ACID DIBUTYLAMIDES | May 2014 | September 2016 | Allow | 32 | 2 | 0 | Yes | Yes |
| 14131059 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | April 2014 | May 2019 | Allow | 60 | 5 | 1 | Yes | Yes |
| 14124956 | COMPOUNDS FOR USE IN THE TREATMENT OF IMMUNE RELATED INFLAMMATORY DISEASE | December 2013 | September 2015 | Allow | 21 | 1 | 1 | No | No |
| 14073991 | 2-THIO-1,3,4-OXADIAZOLES AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | November 2013 | July 2014 | Allow | 8 | 0 | 1 | No | No |
| 14003445 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | September 2013 | October 2017 | Allow | 49 | 4 | 1 | No | No |
| 14003423 | QUINOLINONE DERIVATIVES | September 2013 | February 2015 | Allow | 17 | 1 | 1 | No | No |
| 13883847 | DIPHENYL SULFIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT WHICH CONTAINS SAME AS ACTIVE INGREDIENT | June 2013 | January 2015 | Allow | 20 | 2 | 0 | No | No |
| 13991025 | NOVEL COMPOUND AND MEDICAL USE THEREOF | May 2013 | November 2013 | Allow | 6 | 0 | 0 | No | No |
| 13703481 | ANTIVIRAL COMPOUNDS | April 2013 | November 2014 | Allow | 23 | 1 | 1 | No | No |
| 13839936 | Acyclovir Formulations | March 2013 | October 2014 | Allow | 19 | 1 | 1 | No | No |
| 13823671 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | March 2013 | November 2014 | Allow | 20 | 1 | 1 | Yes | No |
| 13715432 | OPIOID-CONTAINING ORAL PHARMACEUTICAL COMPOSITIONS AND METHODS | December 2012 | June 2014 | Allow | 18 | 1 | 1 | No | No |
| 13704109 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | December 2012 | May 2015 | Allow | 29 | 1 | 1 | Yes | No |
| 13583974 | INDAZOLE COMPOUNDS AND THEIR USES | December 2012 | October 2014 | Allow | 25 | 1 | 1 | No | No |
| 13698501 | mTOR SELECTIVE KINASE INHIBITORS | November 2012 | August 2014 | Allow | 20 | 1 | 1 | No | No |
| 13634732 | Inhibitor Compounds OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASES | October 2012 | August 2015 | Allow | 35 | 3 | 1 | No | No |
| 13509483 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR DIABETES | June 2012 | July 2016 | Allow | 50 | 5 | 0 | Yes | No |
| 13484505 | COMPOSITION FOR MEASURING THE BINDING AFFINITY BETWEEN NUCLEIC ACID AND TEST SUBSTANCE, AND USE THEREOF | May 2012 | January 2014 | Allow | 20 | 2 | 0 | No | No |
| 13457867 | CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALTS | April 2012 | August 2013 | Allow | 16 | 1 | 1 | No | No |
| 13296061 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | November 2011 | May 2013 | Allow | 18 | 1 | 1 | Yes | No |
| 13201331 | METHOD OF TREATING SKIN WITH INGENOL MEBUTATE | October 2011 | July 2018 | Allow | 60 | 6 | 0 | Yes | No |
| 13215914 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | August 2011 | October 2012 | Allow | 14 | 0 | 0 | No | No |
| 13194832 | CAVITY INDUCED ALLOSTERIC MODIFICATION OF INTERMOLECULAR INTERACTIONS AND METHODS OF IDENTIFYING COMPOUNDS THAT EFFECT THE SAME | July 2011 | March 2014 | Allow | 31 | 3 | 1 | No | No |
| 13142784 | OPIOID-CONTAINING ORAL PHARMACEUTICAL COMPOSITIONS AND METHODS | June 2011 | October 2012 | Allow | 15 | 2 | 0 | Yes | No |
| 12666080 | ASCORBATE, VITAMIN K3 AND HYDROXYTOLANS IN THE TREATMENT OF CANCER | March 2011 | October 2013 | Allow | 46 | 1 | 1 | No | No |
| 13057401 | PHARMACEUTICAL COMPOSITION CONTAINING 1,2-DITHIOLTHIONE DERIVATIVE FOR PREVENTING OR TREATING DISEASE CAUSED BY OVEREXPRESSION OF LXR-ALPHA | February 2011 | January 2016 | Allow | 60 | 4 | 1 | Yes | No |
| 12904424 | Wound And Mucosa Antiseptic Based on Bispyridiniumalkanes | October 2010 | April 2014 | Allow | 42 | 3 | 1 | No | No |
| 12671082 | PROCESS FOR THE PREPARATION GLATIRAMER ACETATE (COPOLYMER-1) | September 2010 | December 2014 | Allow | 58 | 2 | 0 | No | No |
| 12863271 | DERIVATIVES OF TAXOL AND CLOSELY RELATED COMPOUNDS | July 2010 | July 2013 | Allow | 36 | 1 | 1 | Yes | No |
| 12681291 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | June 2010 | July 2014 | Allow | 52 | 2 | 1 | Yes | No |
| 12808801 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | June 2010 | February 2015 | Allow | 56 | 4 | 1 | No | No |
| 12445180 | PHARMACEUTICAL COMBINATIONS | March 2010 | July 2014 | Allow | 60 | 2 | 1 | Yes | Yes |
| 12529540 | Ferrate(VI)-Containing Compositions and Methods of Using Ferrate(VI) | March 2010 | November 2013 | Allow | 50 | 3 | 1 | Yes | No |
| 12597281 | G-PROTEIN-CONJUGATED RECEPTOR AGONIST | January 2010 | August 2012 | Allow | 34 | 1 | 1 | No | No |
| 12387510 | METHODS FOR TREATMENT OF NOCTURIA | May 2009 | August 2011 | Allow | 27 | 4 | 0 | Yes | No |
| 12280893 | METHODS FOR PREDICTING CARDIAC TOXICITY | March 2009 | February 2014 | Allow | 60 | 3 | 1 | Yes | No |
| 12305744 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | December 2008 | March 2012 | Allow | 39 | 1 | 0 | No | No |
| 12278019 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | August 2008 | April 2012 | Allow | 45 | 1 | 1 | No | No |
| 12163192 | THERAPEUTIC USES OF GLUTATHIONE MIMICS | June 2008 | December 2014 | Allow | 60 | 6 | 1 | No | No |
| 11983584 | Inhibitors of the mevalonate pathway of streptococcus pneumoniae | November 2007 | December 2013 | Allow | 60 | 4 | 1 | Yes | No |
| 11591324 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | November 2006 | August 2011 | Allow | 58 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEE, WILLIAM Y.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 60.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner LEE, WILLIAM Y works in Art Unit 1623 and has examined 85 patent applications in our dataset. With an allowance rate of 76.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner LEE, WILLIAM Y's allowance rate of 76.5% places them in the 35% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by LEE, WILLIAM Y receive 2.02 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by LEE, WILLIAM Y is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +11.6% benefit to allowance rate for applications examined by LEE, WILLIAM Y. This interview benefit is in the 50% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 22.2% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 52.6% of cases where such amendments are filed. This entry rate is in the 73% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 47.6% are granted (fully or in part). This grant rate is in the 55% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.4% of allowed cases (in the 79% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.1% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.